RBC Capital Bullish on ADC Therapeutics S.A. (ADCT) on Lymphoma Treatment Development

ADC Therapeutics (NYSE:ADCT) is one of the best multibagger penny stocks to buy right now. On December 4, Guggenheim analyst Michael Schmidt reaffirmed his Buy rating on ADC Therapeutics (NYSE:ADCT) and set a price target of $10.00. On December 3, RBC Capital reiterated an Outperform rating and $5.00 price target in response to interim Phase Ib data from the LOTIS-7 trial.

RBC Capital Bullish on ADC Therapeutics S.A. (ADCT) on Lymphoma Treatment Development

Data from the LOTIS-7 trial evaluating the safety and efficacy of ZYNLONTA demonstrated a manageable safety profile and strong efficacy, including deep and durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma.

The trial demonstrated an overall response rate of 89.8% and a complete response rate of 77.6% across 49 efficacy-evaluable patients. The topline results affirm the potential of ZYNLONTA and glofitamab as the best-in-class bispecific antibody-based combination in 2L+ DLBCL.

“Taken together with the LOTIS-5 trial, for which top-line results are anticipated in the first half of 2026, we believe ZYNLONTA-based combinations offer complementary approaches with the potential to improve outcomes for 2L+ DLBCL patients,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.

Amid positive trial results, ZYNLONTA has already received accelerated approval from the FDA and conditional approval from the European Commission as a treatment option for relapsed or refractory diffuse large B-cell lymphoma.

ADC Therapeutics S.A. (NYSE:ADCT) is a commercial-stage biotech company that develops targeted cancer drugs called Antibody-Drug Conjugates (ADCs), using its proprietary Pyrrolobenzodiazepine (PBD) technology. It uses the technology to link potent chemotherapy to antibodies that find and kill cancer cells, with an approved drug (Zynlonta) for lymphoma.

While we acknowledge the potential of ADCT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ADCT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: Billionaire David Tepper’s Top 12 Stock Picks Heading into 2026 and 12 Best Industrial Stocks to Buy According to Wall Street Analysts.

Disclosure: None. This article is originally published at Insider Monkey.